The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Search Results for: cardiocomm

Q4 2013 and Annual Share Price Performance for the Canadian Healthcare Sector: Strong and volatile performance for the smaller cap public companies (Part 2)

In this blog, I will focus on the Canadian public healthcare companies which started 2013 with share prices between $0.10 and $0.99 (53 companies). The results for the larger companies covered in Part 1 of this blog were strong. The results for the smaller cap companies were also strong – average annual share price increase […]

Monday Deal Review: October 15, 2012

Welcome to your Monday Biotech Deal Review for October 15, 2012.  Thanks to Thanksgiving for the Canadians and Columbus day for the Americans out there, this week’s post covers the last two weeks of activity.  Biggest of the weeks’ stories, however, is Aeterna Zentaris Inc.’s $15 million public offering, closing in mid October.  Read onwards to see just how […]

Monday Biotech Deal Review: July 30, 2012

Welcome to your Monday Biotech Deal Review for Monday July 30, 2012.  Highlights from the previous weeks include the closing of the $13 million public offering by Trimel Pharmaceuticals and $7.5 million loan, as well as the M&A activity involving Functional Technologies Inc. and Medifocus Inc. Read on to learn more. 

Monday Biotech Deal Review: July 9, 2012

Welcome to your Monday Biotech Deal Review for July 9, 2012.  Highlights from the previous two weeks include the announcement of a $13.25 million prospectus offering by Trimel Pharmaceuticals, and the announcement of a $200 million exchange offer by Angiotech on its Senior Floating Rate Notes due 2013.  Read on to learn more.

Monday Biotech Deal Review: February 13, 2012

Welcome to your Monday Biotech Deal Review for February 13, 2012.  There was some interesting biotech activity over the previous two weeks, including the closing by Oncolytics of its $18.5M equity financing and the withdrawal by Valeant of its offer to acquire ISTA Pharmaceuticals and its acquisition of a Brazilian food and sport supplement company.  […]

Monday Biotech Deal Review: August 8, 2011

Welcome to your Monday Biotech Deal Review for August 8, 2011.  The previous two weeks witnessed a flurry of investment activity, including the filing of final prospectuses by each of Lorus Therapeutics and Atrium Innovations in respect of equity and debt offerings, respectively.  Read on to learn more. 

Monday Biotech Deal Review: July 11, 2011

Welcome to your Monday Biotech Deal Review for July 11, 2011.  This week is a double feature, owing to last week’s break due to both Canada Day and Fourth of July holidays.  There was a lot of activity over the past two weeks in the biotech space.   Read on to catch up! 

Monday Biotech Deal Review: June 6, 2011

Welcome to your Monday Biotech Deal Review for June 6, 2011.  This week’s deal review is brought to you by Norton Rose OR LLP summer student Steven Zuccarelli who, before entering law school at Osgoode Hall Law School, obtained his B.Sc and M.Sc at McMaster University in Biochemistry and Health Sciences, respectively, where he was […]

Monday Biotech Deal Review: April 18, 2011

Welcome to your Monday Biotech Deal Review for April 18, 2011.  Just by way of FYI, readers may be interested to know that The Canadian Institute will be hosting its 5th annual conference on Drug Pricing and Reimbursement in Canada in Toronto from June 14 – 15 at the Sutton Place Hotel.  The conference aims […]

Monday Biotech Deal Review: March 29, 2011

Welcome to your Monday Biotech Deal Review for March 28, 2011.  There was a flurry of financing activity last week, with over $76M raised or announced in biotech funds (not including the $60M Genome Canada investment announced by the Government of Canada).  Double-digit million-dollar deals included MethylGene’s $34.5M private placement announcement, Medicago’s $17M private placement […]

Monday Biotech Deal Review: March 14, 2011

Welcome to your Monday Biotech Deal Review for March 14, 2011.  This week was a fairly slow week for Canadian biotech, but there were nevertheless a couple of interesting announcements.  Pharmagesic acquired over 90% of the restricted voting shares of WEX Pharmaceuticals marking the conclusion of its bid, and Theratechnologies has backed away from its […]

Monday Biotech Deal Review: February 21, 2011

Welcome to your Monday Biotech Deal Review for February 21, 2011.  Among other news, Angiotech made some progress this week in CCAA proceedings with respect to its recapitalization, and Merck Canada has made another investment in Quebec’s biopharma sector, investing $6.8M.  Read on to learn more.  

Monday Biotech Deal Review: February 7, 2011

Welcome to your Monday Biotech Deal Review for February 7, 2011.  It was a fairly busy week for Canadian biotech – Angiotech has followed suit in the U.S. on the heels of last week’s CCAA filing, a number of acquisitions were announced, and there was some activity in biotech licensing.  Read on to learn more. 

Monday Biotech Deal Review: January 3, 2011

Happy New Year, and welcome to the first Monday Biotech Deal Review of 2011!  There were only a handful of items to report on from last week, as the holiday season brought the usual corporate slow-down.  Nevertheless, the week saw the completion of a couple of private placements (CardioComm and Ondine Biomedical), along with the […]

Monday Biotech “Happy Holidays” Deal Review: December 27, 2010

Welcome to your Monday Biotech “Happy Holidays” Deal Review!  For those who may have noticed, last week the Monday Biotech Deal Review took its own holiday, so this week’s digest contains biotech news spanning the past two weeks – to ensure you don’t miss a single drummer boy’s beat.  It has been a busy two […]

Monday Biotech Deal Review: November 22, 2010

Welcome to your Monday Deal Review.  There was quite a bit of Canada / U.S. crossborder investment activity last week, with a $700M note offering by Valeant, IMRIS’ USD$52M public offering, and both IMRIS and Tekmira announcing their listing on the NASDAQ.   Read on to learn more, as well as the usual summaries of recent […]

Monday Biotech Deal Review: October 25, 2010

Welcome to your weekly review of Canadian biotech deals for October 25, 2010.  Last week’s notable transactions included the Qualifying Transaction of TSXV CPC company CCS Capital Inc. (now known as China Health Labs & Diagnostics Ltd.) and ProMetic’s strategic agreement with Allist Pharmaceuticals Inc., for the commercialization in China of two of ProMetic’s drug […]

Monday Biotech Deal Review: August 9, 2010

Catching up from the long weekend last week, we have a full two weeks’ worth of deals to bring you. Highlights include $16.7 million of securities closings, $8.25 million launched; and interesting developments in the Forbes Medi-Tech and Northstar Healthcare acquisitions. Check out what the last two weeks have wrought…

Monday Biotech Deal Review: May 31, 2010

Things are picking up a bit this week, with a few new financings, some collaboration agreements and a deal in the venture capital community that coincided with the CVCA’s annual meeting.

Monday Biotech Deal Review: May 10, 2010

Some people were on the move this week — not only did Sanofi Canada announce 70 R&D job cuts, but BioMS took on a new banker and Labopharm, CardioComm and GeneNews all get new faces. Despite the fact that it seemed half of the country’s companies and deal-makers were at BIO in Chicago this week, there […]

Monday Biotech Deal Review: April 19, 2010

This week’s deals are headlined by Æterna Zentaris’ $15 million placement (on the back of positive regulatory news over the last couple of weeks). Æterna Zentaris’ is joined by a passel of other private placements, but not much else.  As a bonus for a slow deal week, though, we’ll throw in a name change and […]

Monday Biotech Deal Review: March 29, 2010

This week’s Canadian biotech deals include an acquisition by Biovail, Hæmacure’s BIA filing comes to a predictable end, MethylGene finds $8.9 million in its couch cushions from some Ontario numbered corps, Leap Medical leaps ahead with $1 million from MSBiV and other Quebec favourites, and BioSyntech borrows against its SR&EDs.  Those, plus more securities, debt […]

Monday Biotech Deal Review: November 30, 2009

It was a fairly quiet week last week, but you still have options (har) after the jump, as well as an equity line, a debt settlement, a rights offering, licenses, and deals closing in a reasonably timely manner.

Follow

Get every new post delivered to your Inbox.

Join 131 other followers